Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

32.1K
Overview
32.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignancies.

Frontiers in immunology·2026
Same author

Diagnostic Approach and Management of Iliac Artery Endofibrosis in Athletes: A Scoping Review.

Vascular specialist international·2025
Same author

A tale of two TROP-2 antibody-drug conjugates: a comparative saga of datopotamab deruxtecan and sacituzumab govitecan.

The oncologist·2025
Same author

HSR25-148: The State of Lung Cancer in Alabama.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

A "Mismatched" connection: a rare case of indirect or dural carotid-cavernous fistula: a case based review.

Annals of medicine and surgery (2012)·2024
Same author

Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?

Cancers·2024

Related Experiment Video

Updated: Nov 20, 2025

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.1K

pH-responsive antibodies for therapeutic applications.

Tomasz Klaus1, Sameer Deshmukh2

  • 1Research and Development Department, Pure Biologics, Inc., Dunska 11, 54427, Wrocław, Poland.

Journal of Biomedical Science
|January 23, 2021
PubMed
Summary

pH-responsive antibodies are engineered biologics that target specific disease sites, like tumors, by responding to pH changes. These next-generation therapies offer improved efficacy and reduced side effects in cancer treatment.

Keywords:
Antibody generationCAR-T cellsRecycling antibodiesSweeping antibodiesTumor microenvironmentpH-responsive antibodies

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.3K

Related Experiment Videos

Last Updated: Nov 20, 2025

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay
07:52

Detection of Antibodies That Neutralize the Cellular Uptake of Enzyme Replacement Therapies with a Cell-based Assay

Published on: September 10, 2018

9.1K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium
09:45

Production of Monoclonal Antibodies Targeting Aminopeptidase N in the Porcine Intestinal Mucosal Epithelium

Published on: May 18, 2021

2.3K

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Background:

  • Therapeutic antibodies are crucial for disease treatment but require enhanced efficacy and specificity.
  • pH-responsive antibodies are emerging as a promising approach to modulate antibody function based on environmental pH.

Purpose of the Study:

  • To review the suitability and examples of pH-responsive antibodies.
  • To discuss their application in targeting the tumor microenvironment and improving drug delivery.
  • To explore their potential in engineering chimeric antigen receptor T-cells (CAR-T).

Main Methods:

  • Literature review of pH-responsive antibodies and their applications.
  • Analysis of antigens targeted by pH-responsive, sweeping, and recycling antibodies.
  • Discussion of antibody applicability in CAR-T cell engineering and blood-brain barrier crossing.

Main Results:

  • pH-responsive antibodies demonstrate functional modulation by the tumor microenvironment.
  • These antibodies show potential in targeting acidified tumor microenvironments, enhancing spatial persistence.
  • Reduced on-target, off-tumor toxicities are observed due to targeted activity.

Conclusions:

  • pH-responsive antibodies are next-generation programmable biologic drugs with significant therapeutic potential.
  • They are valuable for targeting the tumor microenvironment, offering improved spatial persistence and reduced toxicity.
  • Programmable pH-dependent antibodies are predicted to become powerful tools in cancer therapies.